Dr. Henry Levine, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 943
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Johns Hopkins University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
FL license ME39594
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Orlando Health Orlando, FL
- Orlando Health South Lake Hospital Clermont, FL
- Orlando Health-Health Central Hospital Ocoee, FL
- Adventhealth New Smyrna Beach New Smyrna Beach, FL
Medical groups
- Gastroenterology Assoc of Central Fl (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 943
- Services billed
- 6,831
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 270 | 237 |
| Established patient office or other outpatient visit, 20-29 minutes | 229 | 207 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 216 | 214 |
| New patient office or other outpatient visit, 30-44 minutes | 206 | 206 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 171 | 171 |
| Biopsy of large bowel using a flexible endoscope | 141 | 140 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 95 | 95 |
| New patient office or other outpatient visit, 45-59 minutes | 76 | 76 |
| Diagnostic exam of large bowel using a flexible endoscope | 56 | 56 |
| Administration of chemotherapy into vein, 1 hour or less | 46 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Orlando, FL | 335 |
| Omeprazole Other prescribers in Orlando, FL | 226 |
| Pantoprazole Sodium Other prescribers in Orlando, FL | 174 |
| Dicyclomine Hcl Other prescribers in Orlando, FL | 68 |
| Skyrizi On-Body (risankizumab-rzaa) | 58 |
| Creon (lipase/protease/amylase) Other prescribers in Orlando, FL | 42 |
| Famotidine Other prescribers in Orlando, FL | 42 |
| Esomeprazole Magnesium Other prescribers in Orlando, FL | 38 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in Orlando, FL | 28 |
| Budesonide Dr (budesonide) Other prescribers in Orlando, FL | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 57 payments worth $1,445 in total to this clinician.
| AbbVie Inc. | $491 |
|---|---|
| Madrigal Pharmaceuticals | $277 |
| Janssen Biotech, Inc. | $199 |
| Celltrion USA Inc. | $134 |
| Enterra Medical, Inc. | $122 |
| Ipsen Biopharmaceuticals, Inc | $62.98 |
| Genzyme Corporation | $43.78 |
| Regeneron Healthcare Solutions, Inc. | $38.96 |
| Food and Beverage | $1,445 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 4 companies. The companies reported $587,667 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sanofi US Services Inc. · Active, not recruiting · NCT06557772 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
AbbVie Inc. · Recruiting · NCT06548542 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
AbbVie Inc. · Active, not recruiting · NCT06063967 - M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease
AbbVie Inc. - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie Inc. · Active, not recruiting · NCT06880744 - M24-885 - Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)
AbbVie Inc. - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
AbbVie Inc. · Active, not recruiting · NCT03398135 - ??A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis?. ??Efficacy and S…
Janssen Research & Development, LLC - A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)
Janssen Research & Development, LLC - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.